Login to Your Account



Acucela Kicks off U.S. Study of Japanese Dry Eye Drug

By Catherine Shaffer
Staff Writer

Friday, July 20, 2012

Acucela Inc., of Seattle, began a Phase III trial of 2 percent rebamipide ophthalmic suspension for dry eye syndrome. The trial will support eventual U.S. regulatory submission for the product, already launched in Japan as Mucosta by Otsuka Pharmaceutical Co. Ltd.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription